Preface

As the editor-in-chief of “Current Drug Research Reviews” (CDRR, online ISSN: 2589-9783, print ISSN: 2589-9775; formerly Current Drug Abuse Reviews), a peer-reviewed journal, I wish a warm welcome to all the readers to this new volume. CDRR is an international peer-reviewed journal, which publishes research articles, review articles and clinical studies on the design and development of new drugs, including drug targeting, medicinal chemistry, in-silico drug design, combinatorial chemistry, meta-analyses, drug abuse and addiction, drug-drug interactions and enzyme kinetics; species scaling and extrapolations; drug transporters; target organ toxicity and inter-individual variability in drug exposure-response; extrahepatic metabolism; bio-activation, reactive metabolites, high-throughput screening, drug targets and structure-activity relationships. Currently, CDRR is indexed in BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Scopus, MEDLINE/PubMed, EMBASE/Excerpta Medica, Chemical Abstracts Service/SciFinder, ProQuest, ChemWeb, Google Scholar, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, Ulrich’s Periodicals Directory, QOAM has successfully completed 12 years of scientific publications.

During 2020, our life changed a lot due to the novel virus named, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the COVID-19 disease. It was particularly amazing and a real motive of scientific pride that in just a few months, we have had a new vaccine on the market, which came as a Christmas gift. Indeed, it is hard to find another moment in history with so many scientists devoting their attention to one subject with such speed. The peer-review became more than ever for some periods “saturated” with reduced capacity to scrutinize research, especially those related to pharmacological treatments proposed for COVID-19 with retractions occurring just a few days after acceptance. Although specific treatments were not yet developed, the list of tested drugs does not stop to increase with advances and setbacks. By 2021, we aim to publish at least one special issue in drug research for COVID-19. It is the objective of CDRR that this special issue will be composed of articles extensively covering a specific drug or a class of drugs. We, therefore, encourage all CDDR readers to submit an article to this special issue focusing on the in vitro and in vivo animal and human pharmacological and toxicological mechanisms of drugs. CDRR will continue to be a platform for more detailed discussions on the topics of pharmacokinetics, pharmacodynamics, and analytics aspects of drugs.

My last words are dedicated authors and reviewers, outstanding talented experts who have generously contributed with their knowledge to CDRR improvement, and to the in-house team, particularly Rimsha Najam, Assistant Publication Manager, who coordinated all the administrative submission steps, including typesetting and proof corrections.

Ricardo Jorge Dinis-Oliveira

( Editor-in-Chief)

University Institute of Health Sciences – CESPU, Crl.,
Faculty of Medicine and UCIBIO-REQUIMTE - University of Porto.
Central de Gandra Street, 1317
4585-116 Gandra, PRD
Portugal

E-mails: ricardo.dinis@iucs.cespu.pt; ricardinis@med.up.pt